The Journal is Indexed in
7 - L-Carnitene Effects On Anemia And The Response To Erythropoietin Treatment in Hemodialysis Patients
Yalçın Özbahar, Özçelik Okayer, Özlem Harmankaya, Aydoğan Öbek
OBJETIVE AND STUDY DESIGN: Although L-cartine administration has been slıown to result in an hematocrit in patients with end-stage renal disease, there is little data to demoııstrate that L-carnitene supplementation to hemodialysis patients under recombinant human erythropoietin (r-HuEPO) nıaintenance treatment could improve the response to-HuEPO treatment .To demonstrate whether L-carnitene treatment could furtlıer improve the anemia in dialyzed patients under r-HuEPO therapy, leading to a reduction in r-HuEPO reguirements, L-carnitene ( 1 g intravenously after every dialysis session) was administered for six months to a group of ten patients; the results were compared with datafrom placebo control group(n±IO).
RESULTS: L-carnitene treatment promoted 59% reduction in r-HuEPO (from 7000±2372 U/ week ıo,4900±3355 U/week;p<0,05 in placebo control group,r-HuEPO reguirements did not change signifıcantly (!rom 6400±2630 U/week ıo 7000±2610 U/ week;p> 0,05).
CONCLUSION: it is concludeddthat L-carnitene defıciency might promote EPO resistance in dialyzed patients which is corrected by L-carnitene supplementation, Ultimately reducing r-HuEPO reguirements.
To read full article click